Non-Small Cell Lung Cancer Coverage from Every Angle

Osimertinib Treatment in T790M-Positive NSCLC With CNS Metastases

By: Andrew Goldstein
Posted: Wednesday, September 19, 2018

Osimertinib demonstrated consistently superior central nervous system (CNS) efficacy compared with platinum/pemetrexed in patients with EGFR T790M–positive advanced non–small cell lung cancer (NSCLC) with CNS metastasis. These results from the AURA3 trial were reported by Yi-Long Wu, MD, of the Guangdong Lung Cancer Institute, Guangzhou, China, and colleagues in the Journal of Clinical Oncology. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI).

A total of 419 patients with T790M-positive NSCLC who previously received a first-line EGFR-TKI were randomized to 2:1 to receive osimertinib or platinum/pemetrexed treatment. A total of 116 patients had measurable and/or nonmeasurable CNS lesions, including 46 with measurable CNS lesions.

The overall response rate for patients with measurable lesions was 70% in the osimertinib arm, compared with 31% for the platinum/pemetrexed arm. For patients with measurable and nonmeasurable lesions, the overall response rates were 40% and 17% for osimertinib and platinum/pemetrexed, respectively. The median CNS duration of response for osimertinib and platinum/pemetrexed in those with measurable and/or nonmeasurable CNS lesions was 8.9 months and 5.7 months, respectively. Osimertinib also yielded a higher disease control rate than platinum/pemetrexed, 93% vs. 63%. Additionally, osimertinib had a 78% reduction in the risk of CNS disease progression, with a longer median CNS progression-free survival than the combination therapy (11.7 vs. 5.6 months).

“This is the first global phase III study showing a clear improvement in CNS [overall response rate] with an EGFR-TKI,” the investigators noted.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.